Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v11-FR Version v7-FR
Language French French
Date Updated 2019-03-01 2019-03-01
Drug Identification Number 02468220 02468220
Brand name LENVIMA LENVIMA
Common or Proper name Lenvatinib Lenvatinib
Company Name EISAI LIMITED EISAI LIMITED
Ingredients LENVATINIB LENVATINIB
Strength(s) 8MG 8MG
Dosage form(s) CAPSULE CAPSULE
Route of administration ORAL ORAL
Packaging size 8mg daily-dose carton containing 6 blister cards (each 5-day blister card contains ten 4mg capsules) 8mg daily-dose carton containing 6 blister cards (each 5-day blister card contains ten 4mg capsules)
ATC code L01XE L01XE
ATC description OTHER ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2019-02-19
Actual start date 2019-02-19 2019-02-19
Estimated end date 2019-03-01
Actual end date 2019-02-28 2019-03-01
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Supply of 4mg capsules available through other daily-dose configurations. Contact for more information. Supply of 4mg capsules available through other daily-dose configurations. Contact for more information.
Health Canada comments